Welcome to LookChem.com Sign In|Join Free

CAS

  • or

131918-61-1

Post Buying Request

131918-61-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

131918-61-1 Usage

Description

Different sources of media describe the Description of 131918-61-1 differently. You can refer to the following data:
1. Paricalcitol is a synthetic 1,25-dihydroxy vitamin D2 analog. As vitamin D deficiency, associated with chronic kidney disease, leads to an increase in parathyroid hormone (secondary hyperparathyroidism), paricalcitol is used in renal patients to block parathyroid hormone overproduction. Vitamin D deficiency is also a risk factor in cancer, cardiovascular disease, hypertension, and diabetes, and paricalcitol may have applications in those contexts as well.
2. Paricalcitol was launched as Zemplar in the US for the prevention and treatment of secondary hyperthyroidism associated with chronic renal failure. Paricalcitol is a synthetic vitamin D2, namely a novel 1-alpha-hydroxy-19-noranalogue in which the ring A exocyclic methylene group, typical of all vitamin D systems, has been replaced by two hydrogen atoms. Paricalcitol is the first vitamin D analogue marketed for this indication. In patients with chronic renal failure, Paricalcitol appreciably reduced levels of parathyroid hormone (PTH) without a significant difference in the incidence rate for hypercalcemia or hyperphosphatemia when compared with placebo.

Chemical Properties

White Solid

Originator

Abbott (US)

Uses

Different sources of media describe the Uses of 131918-61-1 differently. You can refer to the following data:
1. Synthetic analog of vitamin D. Antihyperparathyroid.
2. Antihyperparathyriod
3. 1,25-Dihydroxy vitamin D2 is a potent agonist of the vitamin D receptor. Paricalcitol is a synthetic 1,25-dihydroxy vitamin D2 analog. As vitamin D deficiency, associated with chronic kidney disease, leads to an increase in parathyroid hormone (secondary hyperparathyroidism), paricalcitol is used in renal patients to block parathyroid hormone overproduction. Vitamin D deficiency is also a risk factor in cancer, cardiovascular disease, hypertension, and diabetes, and paricalcitol may have applications in those contexts as well.

Brand name

Zemplar (Abbott).

Clinical Use

Vitamin D analogue: Treatment and prevention of secondary hyperparathyroidism associated with chronic renal failure

Drug interactions

Potentially hazardous interactions with other drugs None known

Metabolism

Extensively metabolised via hepatic and non-hepatic pathways to form two relatively inactive metabolites. After oral administration of 3 H-paricalcitol, only about 2% of the dose was eliminated unchanged in the faeces, and no parent drug found in the urine. Approximately 70% of the radioactivity was eliminated in the faeces and 18% was recovered in the urine. Most of the systemic exposure was from the parent drug.

Check Digit Verification of cas no

The CAS Registry Mumber 131918-61-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,1,9,1 and 8 respectively; the second part has 2 digits, 6 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 131918-61:
(8*1)+(7*3)+(6*1)+(5*9)+(4*1)+(3*8)+(2*6)+(1*1)=121
121 % 10 = 1
So 131918-61-1 is a valid CAS Registry Number.
InChI:InChI=1/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1

131918-61-1 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • USP

  • (1499403)  Paricalcitol  United States Pharmacopeia (USP) Reference Standard

  • 131918-61-1

  • 1499403-10MG

  • 45,735.30CNY

  • Detail
  • USP

  • (1499414)  Paricalcitol solution  United States Pharmacopeia (USP) Reference Standard

  • 131918-61-1

  • 1499414-3ML

  • 8,693.10CNY

  • Detail

131918-61-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 14, 2017

Revision Date: Aug 14, 2017

1.Identification

1.1 GHS Product identifier

Product name paricalcitol

1.2 Other means of identification

Product number -
Other names Paricalcitol

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:131918-61-1 SDS

131918-61-1Downstream Products

131918-61-1Related news

Effect of Paricalcitol (cas 131918-61-1) on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism08/02/2019

IntroductionSecondary hyperparathyroidism is highly prevalent in kidney transplant recipients, and commonly results in hypercalcaemia; an association to osteopenia and bone fractures has also been observed. Paricalcitol has proved effective to control secondary hyperparathyroidism in chronic kid...detailed

Effects of oral Paricalcitol (cas 131918-61-1) therapy on arterial stiffness and osteopontin in hypertensive patients with chronic kidney disease and secondary hyperparathyroidism08/01/2019

BackgroundArterial stiffness is linked to the progression of atherosclerosis, while activation of vitamin D receptor exerts favorable cardiovascular effects in patients with renal insufficiency. In this study, we investigated the effects of oral treatment with paricalcitol, a potent vitamin D re...detailed

Paricalcitol (cas 131918-61-1) Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients07/31/2019

IntroductionSecondary hyperparathyroidism (SHPT) and vitamin D deficiency are common at kidney transplantation and are associated with some early and late complications. This study was designed to evaluate whether paricalcitol was more effective than nutritional vitamin D for controlling SHPT in...detailed

Perfil antiinflamatorio del Paricalcitol (cas 131918-61-1) en el receptor de trasplante renal07/29/2019

ResumenAntecedentes y objetivosEl paricalcitol, un activador selectivo del receptor de la vitamina D, se utiliza en el tratamiento del hiperparatiroidismo secundario en el receptor de trasplante renal. Estudios tanto clínicos como experimentales realizados en pacientes renales no trasplantados ...detailed

Vitamin D receptor activation by Paricalcitol (cas 131918-61-1) and insulin resistance in CKD07/28/2019

sBackground and aimsThe nature of the link (causal vs non-causal) between low 1,25-OH vitamin D and insulin resistance (IR) in patients with chronic kidney disease (CKD) remains elusive. We have now made a post hoc analysis of the effect of vitamin D receptor activation by paricalcitol on IR in ...detailed

Paricalcitol (cas 131918-61-1) alleviates lipopolysaccharide-induced depressive-like behavior by suppressing hypothalamic microglia activation and neuroinflammation07/27/2019

Depression is highly prevalent in patients suffering from chronic inflammatory diseases. Dysregulated neuroinflammation and concomitant activated microglia play a pivotal role in the pathogenesis of depression. Paricalcitol (Pari), a vitamin D2 analogue, has been demonstrated to exert anti-infla...detailed

Anti-inflammatory profile of Paricalcitol (cas 131918-61-1) in kidney transplant recipients07/26/2019

Background and objectivesParicalcitol, a selective vitamin D receptor activator, is used to treat secondary hyperparathyroidism in kidney transplant patients. Experimental and clinical studies in non-transplant kidney disease patients have found this molecule to have anti-inflammatory properties...detailed

131918-61-1Relevant articles and documents

Synthesis of paricalcitol: A novel strategy combining chemical and microbial transformations

Luo,Jiang,Song,Fang,Lu

, p. 323 - 327 (2017)

A novel strategy was developed for the preparation of paricalcitol (1α,25-dihydroxy-19-norvitamin D2) via seven-step chemical transformation and one-step microbial transformation. Using vitamin D2 as a starting material, 1α- and 25-hydroxyl groups of paricalcitol were introduced by Pseudonocardia autotrophica CGMCC5098 at the late stage of the synthesis, allowing us to avoid harsh reaction conditions and tedious steps. The overall yield of paricalcitol was 0.75%.

Preparation method of paricalcitol isomer impurity PY5

-

Paragraph 0041-0047, (2019/10/23)

The invention discloses a preparation method of paricalcitol isomer impurity PY5. The preparation method comprises the following steps: taking (1R, 3aR, 7aR)-1-((2R,5R,E)-5,6-dimethyl heptyl-3-alkene-2-yl)-7a-methyl octahydro-4H-indole-4-ketone as a start

Purification method for paricalcitol

-

Paragraph 0110-0111; 0116; 0117, (2018/04/01)

The invention provides a purification method for paricalcitol. The method does not need any seed crystal; a crude paricalcitol product is dissolved in a mixed solvent of acetone and water, and heatingreflux is carried out so as to allow the crude paricalcitol product to be completely dissolved; and cooling crystallization is carried out at room temperature, wherein a ratio of the usage amounts ofparicalcitol to the mixed solvent is 1: 20 to 1: 80 (g/ml).

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 131918-61-1